• Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference

    Источник: Nasdaq GlobeNewswire / 22 фев 2024 16:05:00   America/New_York

    SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming TD Cowen 44th Annual Healthcare Conference in Boston, MA.

    Adaptive Biotechnologies’ management is scheduled to present on Monday, March 4th at 11:10 a.m. Pacific Time / 2:10 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

    About Adaptive Biotechnologies

    Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

    ADAPTIVE INVESTORS
    Karina Calzadilla, Vice President, Investor Relations
    201-396-1687
    investors@adaptivebiotech.com

    ADAPTIVE MEDIA
    Erica Jones, Associate Director, Corporate Communications
    206-279-2423
    media@adaptivebiotech.com


    Primary Logo

Опубликовать